T9	Process 144 169	translational realization
T17	Material 211 236	a scalable culture system
T18	Process 199 210	demonstrate
T22	Data 370 391	suspension conditions
T23	Material 402 428	a computational simulation
T29	Process 531 547	Serial passaging
T31	Material 605 618	the E8 medium
T36	Process 656 666	expression
T38	Data 629 651	their normal karyotype
T39	Process 619 628	preserved
T40	Material 761 775	spinner flasks
T41	Material 738 748	The hiPSCs
T42	Process 749 757	cultured
T46	Process 829 840	pluripotent
T51	Method 1005 1025	a xeno-free protocol
T54	Process 1062 1070	recovery
T55	Process 1075 1098	the scalable production
T58	Material 1272 1278	hiPSCs
T61	Process 1323 1344	clinical applications
T62	Process 1163 1195	an efficient scale-up bioprocess
T63	Material 1128 1139	This system
T64	Data 1199 1229	completely xeno-free condition
T66	Material 1414 1423	E8 medium
T68	Material 1437 1465	the first hydrodynamic model
T69	Material 1470 1500	glass-ball type spinner flasks
T70	Process 1517 1538	a scalable bioprocess
T71	Data 1542 1581	completely defined xeno-free conditions
T76	Material 1657 1668	Human iPSCs
T77	Process 1720 1734	the bioprocess
T84	Process 1588 1597	optimized
T1	Material 26 71	human induced pluripotent stem cells (hiPSCs)
T2	Process 0 22	Large-scale production
T3	Process 75 102	robust and economic methods
T4	Material 173 189	hiPSC technology
T5	Process 241 256	hiPSC expansion
T6	Material 263 309	the E8 chemically defined and xeno-free medium
T10	Material 484 529	undifferentiated aggregates in spinner flasks
T11	Material 551 598	two different hiPSC lines in the spinner flasks
T12	Data 670 700	undifferentiated state markers
T14	Process 931 975	mesodermal and hematopoietic differentiation
T15	Process 1029 1057	single-cell cryopreservation
T16	Material 1102 1126	hiPSCs in spinner flasks
T19	Data 1284 1308	the quantity and quality
T20	Material 1369 1407	the first suspension culture of hiPSCs
T21	Process 1598 1628	a single-cell cryopreservation
T24	Material 1633 1653	hiPSCs in suspension
T25	Data 1680 1713	pluripotency and normal karyotype
T13	Material 857 884	in vitro and in vivo assays
T27	Process 1234 1268	the expansion and cryopreservation
T7	Data 316 356	either adherent or suspension conditions
T28	Process 361 369	optimize
T8	Process 455 473	efficiently expand
T30	Material 474 480	hiPSCs
T26	Material 704 712	TRA-1-60
T32	Material 714 719	SSEA4
T33	Material 721 725	OCT4
T34	Material 731 736	NANOG
T35	Data 790 792	10
T37	Process 793 801	passages
T43	Process 904 923	efficiently induced
T44	Process 1669 1679	maintained
